Lucid Diagnostics Inc. LUCD
Set alert
At close · Oct 30
After hours · Oct 30, 7:44 PM ET
- YTD
- -62.86%
- 1 year
- -66.27%
- Open
- 0.4145
- Prev close
- 0.4323
- Mkt cap
- 77.30M
- Vol
- 1.71M
- Avg vol
- 4.90M
- EPS
- -0.44
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.4032
- High
- 0.44
- Forward P/E
- -1.12
- Beta
- 0.00
- Short ratio
- 0.80
- Inst. own
- 4.18%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 12, 2024
- 50-d avg
- 0.90474
- 200-d avg
- 0.87091
- 1y target
- 3.50
News
2 days ago prnewswire.com
PAVmed to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 13, 2026
Conference Call and Webcast at 8:30 AM ET NEW YORK, Oct. 30, 2026 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company,…
3 days ago prnewswire.com
Lucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026
Conference Call and Webcast at 8:30 AM ET NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical…
5 days ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 14.6% to $3.3 during Tuesday's pre-market session. The company's market cap stands at $14.4 million. Pomdoctor (NASDAQ:POM) stock…
6 days ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Surgery Partners (NASDAQ:SGRY) shares moved upwards by 46.9% to $23.14 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. SciSparc (NASDAQ:SPRC)…
1 week ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Bolt Biotherapeutics (NASDAQ:BOLT) shares moved upwards by 58.8% to $6.65 during Friday's regular session. The market value of their outstanding shares is at $7.9 million. Lucid Diagnostics…
-
1 week ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 29.7% to $0.42 during Friday's pre-market session. The company's market cap stands at $63.6 million. Electra Therapeutics (NASDAQ:ETRA)…
1 week ago benzinga.com
Why RingCentral Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
RingCentral surged 15% after beating Q3 estimates and raising FY26 guidance; XXII, LABT and HUBC led premarket gainers, while LNAI fell.
1 week ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 41.9% to $0.46 during Thursday's after-market session. The company's market cap stands at $67.1 million. Aardvark Therapeutics…
-
1 week ago benzinga.com
Lucid Diagnostics Receiving Medicare Payments For Its EsoGuard Esophageal DNA Test; Closed $15M Private Placement Of Its Newly Designated Series C Convertible Prefs To Existing Long-Term Shareholders On October 21
On September 22, Lucid announced that it would begin submitting Medicare claims for EsoGuard tests performed at one of its two CLIA-certified laboratories. Shortly thereafter, the Company began…
1 week ago prnewswire.com
Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing
Lucid is now submitting Medicare claims and receiving payments at EsoGuard's established Clinical Laboratory Fee Schedule rate Series C Preferred Stock private placement with existing long-term…
-
1 week ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Tempest Therapeutics (NASDAQ:TPST) stock rose 8.9% to $0.57 during Wednesday's after-market session. The market value of their outstanding shares is at $10.1 million. Tenax Therapeutics…
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Elutia (NASDAQ:ELUT) stock moved upwards by 17.2% to $0.94 during Thursday's after-market session. The market value of their outstanding shares is at $34.9 million. Intelligent Bio Solutions…
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Nexalin Technology (NASDAQ:NXL) shares increased by 77.8% to $7.61 during Thursday's regular session. The company's market cap stands at $3.5 million. Stablecoin Development (AMEX:SDEV) stock…
1 month ago prnewswire.com
Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways
Medicare Advisory Panel recommends maintaining EsoGuard's original gapfill payment basis under the Clinical Laboratory Fee Schedule AMA CPT Editorial Panel approves a new Category III CPT code for…
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers IM Cannabis (NASDAQ:IMCC) stock rose 108.5% to $3.63 during Friday's pre-market session. The market value of their outstanding shares is at $1.0 million. Alaunos Therapeutics (NASDAQ:TCRT)…
-
2 months ago benzinga.com
Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $9.5
Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and raises the price target from $9.25 to $9.5.
2 months ago benzinga.com
Lucid Diagnostics Could Be 'High In The Queue' For Medicare Coverage Decision, Analyst Says
Lucid Diagnostics confirmed its first LBM win with Concert, opens up 10M covered lives. Analyst maintains Buy rating and $2.50 PT.
2 months ago marketbeat.com
Lucid Diagnostics Eyes Medicare Catalyst for EsoGuard Growth
Lucid Diagnostics NASDAQ: LUCD is positioning its EsoGuard test as a non-invasive tool to identify Barrett's Esophagus, a precancerous condition associated with esophageal cancer, while it awaits a…
2 months ago prnewswire.com
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results
Veris Health accelerated its commercial engagement with OSU-The James Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission Lucid Diagnostics…
2 months ago seekingalpha.com
Lucid Diagnostics Inc. (LUCD) Q2 2026 Earnings Call Transcript
Lucid Diagnostics Inc. (LUCD) Q2 2026 Earnings Call Transcript
2 months ago marketbeat.com
Lucid Diagnostics Q2 Earnings Call Highlights
Lucid Diagnostics NASDAQ: LUCD reported second-quarter revenue of $1.5 million on 2,770 EsoGuard tests, as the company continued to target quarterly test volume of roughly 2,500 to 3,000 tests while…
-
2 months ago benzinga.com
Lucid Diagnostics Q2 2026 Earnings Call: Complete Transcript
Lucid Diagnostics (NASDAQ:LUCD) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs. For…
2 months ago zacks.com
Lucid Diagnostics Inc. (LUCD) Reports Q2 Loss, Lags Revenue Estimates
Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.1 per share a year ago.
2 months ago prnewswire.com
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results
Recognized 2Q26 revenue of $1.5 million Processed 2,770 EsoGuard ® tests Secured first laboratory benefit manager (LBM) EsoGuard coverage policy Conference call and webcast to be held today, August…
-
2 months ago benzinga.com
Lucid Diagnostics Q2 Adj. EPS $(0.08) Misses $(0.07) Estimate, Sales $1.474M Miss $1.943M Estimate
Lucid Diagnostics (NASDAQ:LUCD) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.07) by 33.33 percent. This is a 20 percent increase over losses of…
2 months ago prnewswire.com
Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test
Concert's policy recognizes EsoGuard ® as the only esophageal precancer test meeting its coverage criteria NEW YORK, Aug. 5, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the…
2 months ago prnewswire.com
Lucid Diagnostics to Participate in Upcoming Investor Conferences
NEW YORK, Aug. 4, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed…
3 months ago prnewswire.com
PAVmed to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 14, 2026
Conference Call and Webcast at 8:30 AM ET NEW YORK, July 31, 2026 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company,…
3 months ago prnewswire.com
Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026
Conference Call and Webcast at 8:30 AM ET NEW YORK, July 30, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical…
4 months ago seekingalpha.com
Lucid Diagnostics: Positioned For A Medicare-Driven Inflection
Lucid Diagnostics offers asymmetric upside, with Medicare reimbursement as a near-term inflection point unlocking a $2–3M backlog and accelerating $8.7M quarterly billable demand. Strong underlying…
4 months ago seekingalpha.com
Lucid Diagnostics Inc. (LUCD) Shareholder/Analyst Call Prepared Remarks Transcript
Lucid Diagnostics Inc. (LUCD) Shareholder/Analyst Call Prepared Remarks Transcript
4 months ago benzinga.com
Lucid Diagnostics Misses On Revenue, But 2026 Growth Outlook Lights Up Bull Case
Lucid Diagnostics reported Q1 revenue miss. Analyst significant expects revenue growth in 2026/27. Raises PT to $9.25.
-
4 months ago benzinga.com
Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $9.25
Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and raises the price target from $9 to $9.25.
-
5 months ago benzinga.com
Maxim Group Maintains Buy on Lucid Diagnostics, Lowers Price Target to $2
Maxim Group analyst Anthony Vendetti maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and lowers the price target from $3 to $2.
5 months ago prnewswire.com
PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results
Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission Lucid Diagnostics continued building commercial momentum and strengthened…
5 months ago seekingalpha.com
Lucid Diagnostics Inc. (LUCD) Q1 2026 Earnings Call Transcript
Lucid Diagnostics Inc. (LUCD) Q1 2026 Earnings Call Transcript
5 months ago marketbeat.com
Lucid Diagnostics Q1 Earnings Call Highlights
Lucid Diagnostics NASDAQ: LUCD reported first-quarter 2026 EsoGuard test volume above its pre-Medicare target range, while management said it continues to await a Medicare local coverage…
5 months ago zacks.com
Lucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Misses Revenue Estimates
Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.16 per share a year ago.
-
5 months ago benzinga.com
Lucid Diagnostics Q1 Adj. EPS $(0.07) Beats $(0.08) Estimate
Lucid Diagnostics (NASDAQ:LUCD) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 56.25 percent increase over losses of…
-
5 months ago benzinga.com
Lucid Diagnostics Q1 Sales $1.256M Miss $1.383M Estimate
Lucid Diagnostics (NASDAQ:LUCD) reported quarterly sales of $1.256 million which missed the analyst consensus estimate of $1.383 million by 9.18 percent. This is a 57.00 percent increase over sales…
-
6 months ago benzinga.com
Lucid Diagnostics Prices Underwritten Registered Direct Offering Of 18M Common Shares At $1.00 Per Share
Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the…
6 months ago benzinga.com
Texas Instruments To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday
Top analysts change outlook on top names, like AA, SSSS, TXN, HQY, LUCD, RPM, PAR, ASRT. Morgan Stanley raised AA target, Ascendiant raised LUCD.
-
6 months ago benzinga.com
Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $9
Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and raises the price target from $8.25 to $9.
-
7 months ago benzinga.com
Lucid Diagnostics Q4 Adj. EPS $(0.10), Inline, Sales $1.504M Beat $1.379M Estimate
Lucid Diagnostics (NASDAQ:LUCD) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 47.37 percent increase over losses of $(0.19) per share from the…
-
7 months ago benzinga.com
Earnings Scheduled For March 26, 2026
Earnings Scheduled For March 26, 2026
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
9 months ago benzinga.com
What's Going On With PAVmed Shares Thursday?
PAVmed shares pull back Thursday, possibly retracing recent gains on news its subsidiary, Lucid Diagnostics secured a contract
9 months ago benzinga.com
Why Is PAVmed Stock Skyrocketing Wednesday?
PAVmed Inc. (PAVM) surges as its subsidiary Lucid Diagnostics (LUCD) secures a contract with VA for its cancer prevention test.
-
9 months ago benzinga.com
Lucid Diagnostics Wins VA Contract For EsoGuard, Expanding Esophageal Cancer Screening Across Nationwide VA Healthcare System
Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it…